Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Recent preclinical findings regarding FHD-909 (also known as LY4050784) have shown promising results, indicating the possibility of further development opportunities when used in conjunction with an anti-PD-1 antibody for SMARCA4 (BRG1)-mutant lung cancer. The data suggests that this combination therapy could be effective in targeting this specific type of lung cancer, potentially leading to improved treatment outcomes. This discovery opens up new avenues for research and development in the field of oncology.